Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece
Crossref DOI link: https://doi.org/10.1007/s40261-016-0410-2
Published Online: 2016-05-25
Published Print: 2016-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Tzanetakos, Charalampos
Tentolouris, Nicholas
Kourlaba, Georgia
Maniadakis, Nikos
Text and Data Mining valid from 2016-05-25